Massachusetts 2025-2026 Regular Session

Massachusetts House Bill H2472

Introduced
2/27/25  

Caption

Protecting patient safety regarding non-FDA approved drugs

Impact

If passed, HB 2472 would significantly affect the operations of retail pharmacies in Massachusetts. By prohibiting the resale of compounded medications, the bill aims to maintain strict control over the distribution of these specialized drugs, thereby reducing the potential for misuse and ensuring that they are only dispensed as intended. Violations of this law could lead to disciplinary actions against pharmacies by the state's Board of Registration in Pharmacy, including fines, suspension, or loss of license. This stringent enforcement holds pharmacies accountable for adhering to safe practices in medication preparation and dispensing.

Summary

House Bill 2472, titled 'An Act Protecting Patient Safety Regarding Non-FDA Approved Drugs,' aims to enhance the safety and regulation of compounded medications dispensed by retail pharmacies in Massachusetts. The bill defines compounded medication as any drug prepared by a licensed pharmacist specifically to meet the unique needs of an individual patient. The bill outlines that such medications should not be resold and must only be provided to the patient for whom they were compounded, pursuant to a valid prescription. This regulation is designed to ensure that patients receive safe and effective medications personalized to their needs.

Contention

Supporters of the bill argue that it is a necessary step towards protecting patient safety, particularly in a landscape where non-FDA approved compounded medications can pose significant risks. However, there may be concerns from pharmacy professionals and business owners regarding the potential negative impacts on their practice, including limitations on their ability to serve patients in need of compounded drugs efficiently. The bill's potential implications for patient access to necessary medications could spark debate among stakeholders in the healthcare community who weigh the importance of safety against accessibility.

Companion Bills

MA H5234

Replaced by Study Order

Previously Filed As

MA S1497

Protecting patient safety regarding non-FDA approved drugs

MA S1614

Ensuring home care patient safety

MA HB8310

Patient Safety and Whistleblower Protections Act

MA H1261

Protecting patients from surprise bills related to emergency ambulance service

MA S799

Protecting patients from surprise bills related to emergency ambulance service

MA SB652

Protecting Patients from Deceptive Drug Ads Act

MA SB4086

Patient Safety and Whistleblower Protections Act

MA H2169

Relative to worker compensation protections for certified medical cannabis patients and their caregivers

MA H2442

Protecting patients and healthcare workers from exposure to surgical smoke

MA S1482

Protecting patients and health care workers from exposure to surgical smoke

Similar Bills

VA SB1366

Compounding drugs; exceptions for distribution within hospital or health system.

VA HB1905

Compounding drugs; exceptions for distribution within hospital or health system.

CA AB2442

Peptides.

VA HB917

Compounding pharmacies; use of bulk drug substances, recordkeeping.

HI HB2164

Relating To Workers' Compensation.

VA HB917

A BILL to amend and reenact ยงยง 54.1-3406 and 54.1-3410.2 of the Code of Virginia, relating to Board of Pharmacy; compounding pharmacies; use of bulk drug substances; recordkeeping.

HI SB2751

Relating To Workers' Compensation.

CO SB066

Regulation of Compounded Weight-Loss Medication